Lung Cancer Clinical Trial
Official title:
A Biomarker Study Comparing the Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide in Patients Who Receive Thoracic Radiotherapy
The goal of this clinical research study is to use a new breathing test that measures the amount of nitric oxide (NO) you exhale. Researchers want to compare your "NO" levels to the amount of inflammation in your lungs, as measured using a positron emission tomography (PET) scan reading, and with respiratory symptoms questionnaire.
Lung Cancer Cohort:
NO Breathing Test:
If you agree to take part in this study, you will have a breathing test performed before
starting radiation therapy, weekly during radiation therapy and, about 6 weeks after the end
of radiation therapy on the same day of your restaging PET scan. The breathing test measures
how much NO you exhale while breathing. To complete this test, you will exhale into a device
called an "NO breath analyzer" for 10 seconds. You will repeat this test 3 times. The
results of this test will give researchers information about possible inflammation in your
lungs. The results of this test will be compared to the results of your PET scan.
For the first exhaled NO testing session, and any session in which you produce a high enough
NO level, you will have the NO breath test repeated up to 4 times. The staff will ask you to
exhale at different speeds during these repeated sessions, in order to learn where in your
lungs the NO is coming from.
Respiratory Symptoms Questionnaire:
At each visit when you have NO breathing tests, you will be asked to complete a
questionnaire about your breathing and any symptoms you may be having. A research assistant
will be able to help you with completing the questionnaire. It should take about 10 minutes
to complete the questionnaire.
PET scans:
After completing your radiation therapy, you will receive a PET scan as part of this study.
The PET scan will be scheduled for you between 40 and 50 days after the end of the radiation
therapy. A study staff member will call you with the PET scan date. Ten (10) participants
will receive a second PET scan within 2-7 days after the first PET scan in order to check
reproducibility.
For up to 6 hours before the PET scan, you must not eat or drink anything except water. A
small tube will be placed in your arm, and you will receive an injection of a very small
amount of a mildly radioactive sugar material into your bloodstream. The radioactive nature
of this injected material allows the scanner to "see" it in certain places in your body.
After the injection, you will need to rest quietly until it is time for the scan. The amount
of rest time may vary, but be prepared to wait for between 45 and 90 minutes. During the
scan, you will lie flat on your back on a table. The scan itself may last up to 1 hour.
Length of Study:
You will remain on study for up to 7 months. After you have completed the breathing tests,
blood draws, questionnaires, and PET scans, your participation on this study will be over.
This is an investigational study. The device (called an NO breath analyzer) used in this
study is FDA approved and commercially available for measuring exhaled NO levels in patients
with asthma. The use of the PET scan and blood test to check lung inflammation is also
investigational.
Up to 150 patients (up to 47 with lung cancer) will take part in this study. All will be
enrolled at MD Anderson.
Esophageal Cancer Cohort:
NO Breathing Test:
If you agree to take part in this study, you will have a breathing test performed before
starting radiation therapy, about 5 weeks later after radiation therapy is complete (at the
end of radiation therapy), and the same day of your restaging PET scan. The breathing test
measures how much NO you exhale while breathing. To complete this test, you will exhale into
a device called an "NO breath analyzer" for 10 seconds. You will repeat this test 3 times.
The results of this test will give researchers information about possible inflammation in
your lungs. The results of this test will be compared to the results of your PET scan.
For the first exhaled NO testing session, and any session in which you produce a high enough
NO level, you will have the NO breath test repeated up to 4 times. The staff will ask you to
exhale at different speeds during these repeated sessions, in order to learn where in your
lungs the NO is coming from.
Respiratory Symptoms Questionnaire:
At each visit when you have 3 NO breathing tests, you will be asked to complete a
questionnaire about your breathing and any symptoms you may be having. A research assistant
will be able to help you with completing the questionnaire. It should take about 10 minutes
to complete the questionnaire.
Length of Study:
After you have completed the breathing tests and the questionnaires, your participation on
this study will be over.
This is an investigational study. The device (called an NO breath analyzer) used in this
study is FDA approved and commercially available for measuring exhaled NO levels in patients
with asthma. Its use in patients with esophageal cancer is investigational. The optional
SPECT scans using 99m Tc-HMPAO are an FDA approved standard imaging method for infection
and/or inflammation.
Up to 150 patients (up to 93 with esophageal cancer) will take part in this study. All will
be enrolled at MD Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|